The best place for the Latest Cardiac and Vascular News
LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has expanded its OnTrak-A solution into Florida and Georgia with one of the nation’s leading health plans. This follows OnTrak-A’s expansion into Iowa and Nebraska earlier this month. Eligible […]
KFAR-SABA, Israel–(BUSINESS WIRE)–The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. The publication and trial results were announced today at the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego, California. The FAST-FFR trial demonstrated that the […]
NEW YORK and MELBOURNE, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast’s proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome (HLHS) was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease […]
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San […]
SANTA CLARA, Calif., Sept. 25, 2018 /PRNewswire/ — Based on its recent analysis of the North American heart-on-a-chip market, Frost & Sullivan recognizes TARA Biosystems with the 2018 North American Technology Innovation Award for its trailblazing Biowire™ II heart-on-a-chip platform. This solution produces mature, engineered, human cardiac tissues and demonstrates promise as a valuable […]
BURLINGTON, Mass.–(BUSINESS WIRE)–Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause […]
HANGZHOU, China, CAESAREA, Israel, TAMPA, Florida — September 25, 2018— Venus Medtech (Hangzhou) Inc., the preeminent Chinese transcatheter heart valve company, today announced it has signed an agreement to acquire Keystone Heart Ltd., a privately-held medical device company and makers of TriGUARD 3™. The acquisition gives Venus Medtech international rights to […]
OR YEHUDA, Israel, Sept. 20, 2018 /PRNewswire/ — Cardiovalve announced today that it has commenced the AHEAD USmulticenter study (U.S. Early Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System). AHEAD US trial recruitment will start in early Q4 2018. The primary endpoint of the […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation […]
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 24, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today topline results from the Vascepa® cardiovascular (CV) outcomes trial, REDUCE-IT™, a global study of 8,179 statin-treated adults with elevated CV risk. REDUCE-IT met its primary endpoint demonstrating an approximately 25% relative risk reduction, to […]
